---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-26-000107"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T23:00:38.124634+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated

## Summary
- Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.
- Gross profit $7.2M (+20% YoY); gross margin 61.5% vs 62.8% on tariff costs and production timing.
- Net loss improved 31% to $0.8M ($0.02 diluted EPS) from $1.2M ($0.03) in prior year.
- Cash $8.8M; cash usage $0.1M in Q1. Reiterates FY2026 revenue $47.5-50.0M, positive adjusted EBITDA & cash flow.
- Submitted 510(k) for Freedom Infusion System with deferoxamine; two pharma collaborations advanced to Phase III.

## SEC filing metadata
- accession: 0001161697-26-000107
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169726000107/0001161697-26-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169726000107/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-26-000107
- JSON: https://secwatch.observer/filing/0001161697-26-000107.json
- Plain text: https://secwatch.observer/filing/0001161697-26-000107.txt

## Source-grounded claims
- claim_id: 2e06f836c1b21a551b7b63eb5a115bdd69941a3c
  claim: KORU Medical Systems, Inc. reported first quarter ended March 31, 2026 results: revenue $11.8 million, net income $0.8 million, EPS ($0.02) per diluted share. Guidance reaffirmed.
  evidence_excerpt: financial results for the first quarter ended March 31, 2026. The Company also reiterated guidance for the full year 2026. Recent Highlights ● First quarter 2026 net revenues of $11.8 million grew 22% over the prior year period ● First quarter 2026 gross profit grew 20% over the prior year period to $7.2 million, with gross margin of 61.5% ● First quarter 2026 net
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169726000107/0001161697-26-000107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.